U.S., June 27 -- ClinicalTrials.gov registry received information related to the study (NCT07039747) titled 'Effectiveness of a Dietary Supplement in Irritable Bowel Syndrome' on June 18.
Brief Summary: Irritable bowel syndrome (IBS) affects around 5% of the general population and remains a daily problem in clinicians' practices, with inconsistent efficacy of treatments despite patients' high expectations. Intestinal hyperpermeability and visceral hypersensitivity are the two major components of IBS, and both can disrupt gastrointestinal function and ultimately impair patients' quality of life.
Glutamine is a non-essential amino acid that regulates numerous metabolic pathways and plays a key role in the intestine as it is the preferred su...